Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial

被引：0
|
作者：
Boehm, Michael [1 ]
Butler, J. [2 ]
Filippatos, G. [3 ]
Ferreira, J. P. [4 ]
Pocock, S. J. [5 ]
Abdin, A. [1 ]
Mahfoud, F. [1 ]
Brueckmann, M. [6 ]
Gollop, N. D. [6 ]
Iwata, T. [7 ]
Ponikowski, P. [8 ]
Wanner, C. [9 ]
Zannad, F. [4 ]
Packer, M. [10 ]
Anker, S. D. [11 ]
机构：
[1] Univ Hosp Saarland, Clin Internal Med 3, Cardiol Angiol & Intens Care Med, Homburg, Germany
[2] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA
[3] Natl & Kapodistrian Univ Athens, Med Sch, Athens, Greece
[4] Univ Lorraine, INSERM, Ctr Invest Clin Plurithemat, CICP 1433, Nancy, France
[5] London Sch Hyg & Trop Med, Dept Med Stat, London, England
[6] Boehringer Ingelheim Int, Ingelheim, Germany
[7] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[8] Wroclaw Med Univ, Wybrzeze L Pasteura 1, PL-50367 Wroclaw, Poland
[9] Univ Hosp Wurzburg, Wurzburg, Germany
[10] Baylor Univ, Med Ctr, Dallas, TX USA
[11] German Ctr Cardiovasc Res DZHK, Berlin Inst Hlth Ctr Regenerat Therapies, Dept Cardiol BCRT, Partner Site Berlin, Berlin, Germany
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2022年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：131 / 132
页数：2
相关论文
共 50 条
  • [1] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of blood pressure: the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Saloustros, I.
    Schueler, E.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 132 - 132
  • [2] Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
    Boehm, Michael
    Anker, Stefan
    Mahfoud, Felix
    Lauder, Lucas
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Brueckmann, Martina
    Saloustros, Ilias
    Schueler, Elke
    Wanner, Christoph
    Zannad, Faiez
    Packer, Milton
    Butler, Javed
    [J]. EUROPEAN HEART JOURNAL, 2023, 44 (05) : 396 - 407
  • [3] Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial
    Butler, Javed
    Siddiqi, Tariq Jamal
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Zannad, Faiez
    Anker, Stefan D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (02) : 245 - 248
  • [4] Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial
    Boehm, Michael
    Butler, Javed
    Krawczyk, Marcin
    Mahfoud, Felix
    Haring, Bernhard
    Filippatos, Gerasimos
    Ferreira, Joao Pedro J.
    Pocock, Stuart
    Brueckmann, Martina
    Ofstad, Anne Pernille
    Schueler, Elke
    Wanner, Christoph
    Verma, Subodh
    Packer, Milton D.
    Anker, Stefan
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (08) : 1375 - 1383
  • [5] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and CKD
    Zannad, Faiez
    Kraus, Bettina J.
    Zeller, Cordula
    Pocock, Stuart
    Packer, Milton
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Anker, Stefan D.
    Butler, Javed
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : B3 - B3
  • [6] Outcomes of empagliflozin in patients with heart failure with a preserved ejection fraction and atrial fibrillation or atrial flutter: insights from EMPEROR-Preserved
    Filippatos, Gerasimos
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 134 - 135
  • [7] Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
    Boehm, Michael
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Abdin, Amr
    Mahfoud, Felix
    Brueckmann, Martina
    Gollop, Nicholas D.
    Iwata, Tomoko
    Ponikowski, Piotr
    Wanner, Christoph
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (01) : 1 - 18
  • [8] Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial
    Boehm, M.
    Anker, S. D.
    Mahfoud, F.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Brueckmann, M.
    Linetzky, B.
    Schueler, E.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Butler, J.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 983 - 983
  • [9] EMPAGLIFLOZIN IN HEART FAILURE WITH A PRESERVED EJECTION FRACTION ≥50%: RESULTS FROM THE EMPEROR-PRESERVED CLINICAL TRIAL
    Yousef, Zaheer
    [J]. HEART, 2022, 108 : A79 - A80
  • [10] EFFECTS OF EMPAGLIFLOZIN IN FEMALE AND MALE PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION: RESULTS FROM THE EMPEROR-PRESERVED TRIAL
    Butler, Javed
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 311 - 311
12345